$105 million raised by immuno-oncology startup ALX Oncology

12 February 2020

2019_vials_production_manufacturing_biotech_big

Irish immuno-oncology specialist ALX Oncology has raised $105 million in a series C equity financing, led by Vivo Capital.

New investors included funds managed by Logos Capital, Janus Henderson and Foresite Capital. As part of the financing, Vivo Capital managing director Jack Nielsen and Graham Walmsley, general partner of Logos Capital, will join the firm’s board.

ALX is a clinical-stage biotech startup working on therapies that block the CD47 checkpoint mechanism.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK